MEDICAL STRATEGY



MEDICAL BIOHEALTH EUR

Key Information

WKN: 941135 - ISIN: LU0119891520

The net asset value (NAV) of this fund may be subject to significant fluctuations due to the composition of the portfolio and the management techniques employed

FUND MANAGEMENT



Mario Linimeier
Managing Partner, Head of Portfolio Management



Dr Alexander Jenke
Deputy Head of Portfolio Management, Authorised Signatory

CONTACT PERSON



Martina Beran
Head of Sales, Authorised Signatory
+49(0) 821-259351-15
mberan@medicalstrategy.de

WHY MEDICAL STRATEGY

- Focus on leading developers of innovative therapies
- Focus on small and mid-cap companies
- Successful investment track record & Outperformance relative to comparable strategies
- Scientists as portfolio managers

WHY BIOTECHNOLOGY

- **Demographic change & rise of lifestyle-related diseases**
- **Independence from macroeconomic and cyclical influences**
- **Strong fundamentals**
- **Expiring patents**
- **Technological progress as a driver of innovation**

Risks: Credit risk: Issuers of debt securities may become insolvent; liquidity risk: in the case of non-exchange-traded securities; counterparty risk: the Fund's counterparties may become insolvent. Risks arising from the use of derivatives: Higher potential returns are accompanied by a higher risk of loss; currency risk: returns may rise or fall due to currency fluctuations; in general, every investment carries the risk of capital loss.

MEDICAL STRATEGY

PERFORMANCE SINCE INCEPTION

- Performance of MEDICAL BioHealth
- Performance of the NASDAQ Biotech Index

MEDICAL BioHealth EUR




Explanation: The BVI method shows the fund's performance assuming reinvestment of returns, but without taking into account individual costs such as initial sales charges

As at: 30 September 2026; Source: vwd; Price indices in EUR; The previous day's closing prices were used for calculating index performance and exchange rate conversion. As the fund is primarily invested in North America, this took the time difference into account. Fund: Performance calculated using gross return (BVI method). The initial sales charge (on investment and reinvestment) was not taken into account, nor were individual costs such as custody fees. If the initial sales charge and custody fees were included, the performance would be lower. Past performance is not an indicator of future performance and is no guarantee of future success.

ANNUAL PERFORMANCE (ROLLING)

- Fund (net), taking into account the maximum initial charge of 5 per cent.
- Fund (gross)



Past performance is not a reliable indicator of future performance. Gross performance (BVI method) takes into account all costs incurred at fund level (e.g. the management fee), whilst net performance additionally takes into account the initial sales charge. Further costs may be incurred individually at client level (e.g. custody fees, commissions and other charges). Source: Anevis Solutions GmbH, own illustration. As at 30 September 2026.

FIVE THERAPEUTIC AREAS WITH STRUCTURAL GROWTH POTENTIAL



Opportunities: Participation in the global growth of the healthcare market, a portfolio of carefully selected companies, a focus on developers of innovative therapies, the expertise of an interdisciplinary team of experts with a scientific background

Risks: Price risk; misjudgements in investment selection are possible; market risk; liquidity risk; currency risks; industry/sector concentration risk within the biotech and healthcare sectors; small- and mid-cap risk (lower liquidity and higher price volatility)

Legal notices: Past performance is not a reliable indicator of future performance. This is a non-binding marketing communication. It is provided for information purposes only and does not constitute a public offer, a recommendation, advice or an invitation to buy or sell fund units, nor should it be regarded as an invitation to make an offer to enter into a contract for an investment service or ancillary service. It does not constitute a recommendation to buy or sell. The information and assessments contained herein do not constitute investment advice or any other recommendation. They are no substitute for individual investment advice. No assurance can be given that the investment objectives will be achieved. Past performance is no guarantee and no indicator of future performance. Please read the prospectus and the Key Information Document (KID) before making a final investment decision. The binding basis for purchasing the fund is the Key Information Document (KID), the currently valid prospectus together with the management regulations or articles of association, the most recently published and audited annual report and the most recently published unaudited half-yearly report, which are available free of charge in German from the management company Hauck & Aufhäuser Fund Services S.A., 1c, rue Gabriel Lippmann, 5365 Munsbach, Luxembourg and at https://medicalstrategy.de/fonds/medical-bio-health. You can also obtain further information by calling +49-821-259351-14 or by emailing relations@medicalstrategy.de. Further detailed information on the opportunities and risks is contained in the prospectus and the key investor information document. Risk class 5 is based on the assumption that the recommended holding period is adhered to. The risk indicator can range from 1 to 7. The actively managed fund portfolio is not managed with reference to a benchmark index. Tax treatment depends on the personal circumstances of the individual investors and may be subject to future changes. The funds of Medical Strategy GmbH were established under German law and are authorised for distribution in Germany, Austria, the Netherlands and Spain. The units of this fund are not intended for distribution in the USA or to US citizens. The management company may decide to revoke the arrangements it has made for the distribution of the units of its undertakings for collective investment, in accordance with Article 93a of Directive 2009/65/EC. Information on investors' rights is available at https://www.hal-privatbank.com/. The opinions expressed in this product information reflect the current, carefully prepared assessment of Medical Strategy GmbH; these may change at any time without prior notice. Medical Strategy GmbH and any third parties from whom Medical Strategy GmbH obtains information accept no liability for the correctness, completeness, timeliness, accuracy or availability of the data made available and displayed as part of this information service, despite having taken care in its procurement and provision. Medical Strategy GmbH and anevis solutions GmbH, which is responsible for the technical production of the presentation and monthly reports, have not verified the data themselves and accept no liability for any losses caused by or arising in connection with the use of this information. Use of this information is at your own risk. Any unauthorised use of this document, in particular its reproduction, processing, forwarding or publication, is prohibited. The author of this document, as well as its affiliated companies, expressly exclude all liability for the accuracy, completeness or timeliness of the information contained herein and the opinions expressed. Any past performance figures, back-test data or historical or forward-looking simulations contained in this document do not constitute a guarantee of future developments. An investment refers to the purchase of fund units and not directly to the underlying assets. As at 26 May 2026. In the 'Biotechnology Equity Funds' category, the MEDICAL BioHealth secured third place over 10 years and first place over 20 years. On methodology: Since 2006, €uro and its sister publications Börse Online and €uro am Sonntag have been presenting the coveted €uro FundAwards. With these awards, we recognise the funds and ETFs that have achieved the best, second-best and third-best performance in their respective investment categories over 1, 3, 5, 10 and 20 years. Around 22,800 funds and ETFs are in the running for the 2026 FundAwards. The awards are presented across 97 asset classes and for the following time periods: 1 year (5,601 funds and ETFs), 3 years (5,464), 5 years (5,287), 10 years (4,508) and 20 years (1,953). The cut-off date for the assessment was 31 December 2026. Funds and ETFs eligible for a FundAward must have a volume of at least 20 million euros and be readily available for purchase by retail investors through banks or on the stock exchange. As at 30 September 2026